We are live on ! Find out more
VRDN icon

Viridian Therapeutics
VRDN

138 hedge funds and large institutions have $906M invested in Viridian Therapeutics in 2024 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 70 increasing their positions, 28 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

150% more repeat investments, than reductions

Existing positions increased: 70 | Existing positions reduced: 28

25% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 16

1% more funds holding

Funds holding: 136 → 138 (+2)

4.03% less ownership

Funds ownership: 113.16% → 109.13% (-4%)

27% less capital invested

Capital invested by funds: $1.24B → $906M (-$338M)

42% less call options, than puts

Call options by funds: $3.99M | Put options by funds: $6.92M

80% less funds holding in top 10

Funds holding in top 10: 5 → 1 (-4)

Holders
138
Holders Change
+2
Holders Change %
+1.47%
% of All Funds
1.99%
Holding in Top 10
1
Holding in Top 10 Change
-4
Holding in Top 10 Change %
-80%
% of All Funds
0.01%
New
20
Increased
70
Reduced
28
Closed
16
Calls
$3.99M
Puts
$6.92M
Net Calls
-$2.93M
Net Calls Change
+$430K

Top Buyers

1
KCM
Kynam Capital Management
New Jersey
+$22.4M
2
BlackRock
BlackRock
New York
+$13.3M
3
NHAS
Novo Holdings A/S
Denmark
+$12.5M
4
TCM
Tang Capital Management
California
+$9.69M
5
MC
Maverick Capital
Texas
+$8.52M

Top Sellers

1
PBA
Paradigm Biocapital Advisors
New York
-$29.6M
2
PA
Perceptive Advisors
New York
-$28M
3
State Street
State Street
Massachusetts
-$23.8M
4
LGM
Logos Global Management
California
-$12.3M
5
GPP
Great Point Partners
Connecticut
-$11.6M
Name Holding Trade Value Shares
Change 		Change in
Stake
GTC
26
Ghost Tree Capital
New York
$7.65M -$516K -37,292 -6%
EP
27
Eversept Partners
New York
$7.38M +$5.89M +425,412 +299%
Two Sigma Advisers
28
Two Sigma Advisers
New York
$6.85M +$3.08M +222,300 +73%
GPP
29
Great Point Partners
Connecticut
$6.5M -$11.6M -835,000 -63%
N
30
Nuveen
North Carolina
$6.48M -$11.5M -834,051 -63%
Charles Schwab
31
Charles Schwab
California
$6.3M +$828K +59,836 +14%
Northern Trust
32
Northern Trust
Illinois
$6.24M +$238K +17,201 +4%
Walleye Capital
33
Walleye Capital
New York
$5.6M +$5.88M +424,960 +7,540%
Two Sigma Investments
34
Two Sigma Investments
New York
$5.46M +$2.67M +192,966 +85%
WP
35
Woodline Partners
California
$5.22M -$526K -38,007 -9%
Fisher Asset Management
36
Fisher Asset Management
Washington
$5.15M +$88.7K +6,410 +2%
EAM
37
Eagle Asset Management
Florida
$4.93M -$904K -65,305 -15%
Russell Investments Group
38
Russell Investments Group
United Kingdom
$4.55M +$388K +28,025 +9%
SCM
39
Soleus Capital Management
Connecticut
$4.42M – – –
Morgan Stanley
40
Morgan Stanley
New York
$4.17M -$3.35M -241,971 -43%
RA
41
Rosalind Advisors
Ontario, Canada
$3.9M – – –
Wellington Management Group
42
Wellington Management Group
Massachusetts
$3.7M +$598K +43,215 +18%
Renaissance Technologies
43
Renaissance Technologies
New York
$3.22M -$195K -14,100 -5%
UBS Group
44
UBS Group
Switzerland
$3M -$2.07M -149,208 -39%
Millennium Management
45
Millennium Management
New York
$2.97M +$2.88M +207,711 +1,015%
Bank of America
46
Bank of America
North Carolina
$2.74M -$3.67M -265,056 -56%
Bank of New York Mellon
47
Bank of New York Mellon
New York
$2.71M +$786K +56,814 +37%
KFO
48
Kopp Family Office
Minnesota
$2.68M +$1.34K +97 +0%
ACP
49
Acuta Capital Partners
California
$2.59M – – –
HS
50
HighVista Strategies
Massachusetts
$2.58M – – –
1
2
3 4 5

VRDN Hedge Fund Activity: Q2 2024 in Review

138 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Viridian Therapeutics (VRDN) for Q2 2024, worth a combined $906M — down 27% from $1.24B a quarter earlier.

Buyers outnumbered sellers: 20 funds opened new VRDN positions and 16 closed out — a net gain of 4 holders — while 70 added to existing stakes and 28 trimmed.

The largest buyer was Kynam Capital Management, adding an estimated $22.4M. The largest seller was Paradigm Biocapital Advisors, cutting an estimated $29.6M.

  • 138 institutional investors held Viridian Therapeutics (VRDN) as of Q2 2024, up from 136 in Q1 2024.
  • Funds reported $906M of Viridian Therapeutics stock for Q2 2024, down 27% quarter-over-quarter.
  • 20 funds opened new Viridian Therapeutics positions in Q2 2024 and 16 closed out, a net change of +4 holders.
  • The largest Viridian Therapeutics buyer in Q2 2024 was Kynam Capital Management, an estimated $22.4M added.
  • The largest Viridian Therapeutics seller in Q2 2024 was Paradigm Biocapital Advisors, an estimated $29.6M sold.

Based on aggregated 13F filings for Q2 2024.